Abstract
Introduction
Alloimmunisation against the D antigen in pregnant RhD-negative women is preventable using anti-D immune prophylaxis1. A combination of antenatal and postnatal anti-D administration has dramatically reduced alloimmunisation of RhD negative women from 16% to 0.3%1,2. Analysis of cell-free foetal DNA (cffDNA) circulating in maternal plasma facilitates non-invasive antenatal testing of the foetal RhD genotype at an early gestational age3,4. Knowledge of the foetal RhD type allows targeted use of antenatal prophylaxis, avoiding unnecessary treatment of RhD-negative women who are carrying a RhD-negative foetus, and are thus at no risk of immunisation. [...]
Downloads
- Abstract viewed - 390 times
- PDF downloaded - 47 times